SCHEMBL16904651

SCHEMBL16904651

O=C(O)Cc1cc(C(=O)c2ccc(Br)cc2)sc1-c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
ALDH1A1 P00352 4/20 0.68
KMT2A Q03164 3/20 0.68
MEN1 O00255 2/20 0.68
HTT P42858 1/20 0.68
RXFP1 Q9HBX9 2/20 0.55
TP53 P04637 2/20 0.55
ABCB11 O95342 1/20 0.47
LMNA P02545 1/20 0.47
PTGS1 P23219 1/20 0.47
ADORA1 P30542 1/20 0.47
PTGS2 P35354 1/20 0.47
HPGD P15428 2/20 0.43
SRD5A2 P31213 1/20 0.41
KDM4E B2RXH2 3/20 0.40
AKR1C3 P42330 1/20 0.40
MAPK14 Q16539 1/20 0.39
ERO1A Q96HE7 1/20 0.38
CLK1 P49759 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16893446 0.90 MAPT (0.57) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL3057661 0.89 KMT2A (0.58) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL3058715 0.87 KMT2A (0.55) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL16904662 0.87 MAPT (0.56) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL3058700 0.87 MAPT (0.56) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL15545929 0.84 MEN1 (0.63) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL15546267 0.82 KMT2A (0.57) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL16907700 0.81 MEN1 (1.00) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL16904654 0.80 MEN1 (0.61) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL16893457 0.80 KMT2A (0.53) MAPTALDH1A1KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT MAPT 46/4885ALDH1A1 1135/4885KMT2A 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.